reports
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Jacob Mekhael
Zealand Pharma Establishes Boston research hub
Zealand announced the establishment of a new research hub in Cambridge, Massachusetts, in the greater Boston area. The facility will serve as Zealand Pharma's primary US address and is expected to be operational from September 2026. Zealand Pharma's Cambridge hub will enhance the company's research platform through AI-driven drug discovery, advanced automation, and next-generation molecule creation, accelerating the translation of scientific insight into innovative medicines. The establishment o...
Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachuset...
Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation Press release – No. 6 / 2026 Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation New research hub in Cambridge, Massachusetts, in the greater Boston area, expands global discovery capabilities, combining Zealand Pharma’s more than 25 years of expertise in peptides and metabolic health with Boston’s biotech innovation ecosystem. Copenhagen, Denmark and B...
Disclosure of a transparency notification from Aberdeen Group plc
Disclosure of a transparency notification from Aberdeen Group plc Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 20 March 2026 – 6 PM CET Disclosure of a transparency notification from Aberdeen Group plc Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from Aberdeen Group plc, dated 16 March 2026. Notification from Aberdeen Group plc On 19 March 2026, Fagron received a transparency notification from Aberdeen Group plc, informing the Company that its shareholding has...
Openbaarmaking van transparantiekennisgeving van Aberdeen Group plc
Openbaarmaking van transparantiekennisgeving van Aberdeen Group plc Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 20 maart 2026 – 18:00 CET Openbaarmaking van transparantiekennisgeving van Aberdeen Group plc Overeenkomstig de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen, ontving Fagron een transparantiekennisgeving van Aberdeen Group plc, gedateerd op 16 maart 2026. Kennisgeving van Aberdeen Group plc Op 19 maart 2026 ontving Fagron een transparantiekennisgeving van Aberdeen Group plc, waarin aan...
Zealand Pharma increases its share capital as a result of the exercise...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 4 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 19, 2026 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 10,530 divided into 10,530 new shares with ...
- Hilde Van Boxstael
- Kristof Samoy
- Livio Luyten
- Thibault Leneeuw
- Thomas Couvreur
- Thibault Leneeuw
Fagron A Clear Path for sustained Double Digit REBITDA Growth
Our analysis of U.S. compounding capacity and utilization shows that North America can sustain double-digit organic growth, driving our 7.4% organic revenue CAGR (25–30) for the group. We expect strong REBITDA growth in 2026, and margin decrease due to acquisitions. Long-term margin upside is well supported by the new U.S. facilities and improved efficiency through centralized manufacturing and vertical integration in LatAm. The market continues to undervalue Fagron by focusing too heavily on ma...
- Kristof Samoy
Ekopak Sharing is Multiplying but Uncertainty Persists around Large Pr...
Ekopak's FY25 results, while showing tighter cost discipline, were overshadowed by the withdrawal of the EPICO infrastructure fund from the Waterkracht project—creating the risk of significant operational delays or even full project loss. Although a new partnership with an infrastructure fund is intended to finance large WaaS installations through off balance sheet SPVs, the first joint project award is yet to be announced. With Waterkracht removed from our numbers, valuation remains demanding, ...
Disclosure of a transparency notification from Mawer Investment Manage...
Disclosure of a transparency notification from Mawer Investment Management Ltd Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 13 March 2026 – 6 PM CET Disclosure of a transparency notification from Mawer Investment Management Ltd Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from Mawer Investment Management Ltd, dated 11 March 2026. Notification from Mawer Investment Management Ltd On 11 March 2026, Fagron received a transparency notification from Mawer Investmen...
Openbaarmaking van transparantiekennisgeving van Mawer Investment Mana...
Openbaarmaking van transparantiekennisgeving van Mawer Investment Management Ltd Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 13 maart 2026 – 18:00 CET Openbaarmaking van transparantiekennisgeving van Mawer Investment Management Ltd Overeenkomstig de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen, ontving Fagron een transparantiekennisgeving van Mawer Investment Management Ltd, gedateerd op 11 maart 2026. Kennisgeving van Mawer Investment Management Ltd Op 11 maart 2026 ontving Fagron een transpa...
- Jerôme Bodin
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
AUTN AUTONEUM HOLDING AG
IDL ID LOGISTICS GROUP
DEC JCDECAUX SA
KCO KLOECKNER & CO SE
FAGR FAGRON SA
EKI EKINOPS SA
MTU MANITOU BF SA
GBT GUERBET SA
ALLAN LANSON-BCC
SDF K+S AG
ENI ENI S.P.A.
REP REPSOL SA
INRN INTERROLL HOLDING AG
ERG ERG S.P.A.
TECN TECAN GROUP AG
KARN KARDEX HOLDING AG
SIGHT GENSIGHT BIOLOGICS SA
SEFER SERGEFERRARI GROUP SA
VIG VIENNA INSURANCE GROUP AG WIENER VERSICHERUNG GRUPPE
POST OSTERREICHISCHE POST AG
FLU FLUGHAFEN WIEN AG
VLTSA VOLTALIA
MAU ETABLISSEMENTS MAUREL & PROM SA
DUFN DUFRY AG
RUI RUBIS SCA
BP. BP P.L.C.
TFF TFF GROUP
MEDCL MEDINCELL SA
ANTIN ANTIN INFRASTRUCTURE PARTNERS
SHEL SHELL PLC
BANB BACHEM HOLDING AG
CAN CANAL+
TRIO TRIODOS BANK N.V.
AUMOV AUMOVIO
- Jerôme Bodin
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
AUTN AUTONEUM HOLDING AG
IDL ID LOGISTICS GROUP
DEC JCDECAUX SA
KCO KLOECKNER & CO SE
FAGR FAGRON SA
EKI EKINOPS SA
MTU MANITOU BF SA
GBT GUERBET SA
ALLAN LANSON-BCC
SDF K+S AG
ENI ENI S.P.A.
REP REPSOL SA
INRN INTERROLL HOLDING AG
ERG ERG S.P.A.
TECN TECAN GROUP AG
KARN KARDEX HOLDING AG
SIGHT GENSIGHT BIOLOGICS SA
SEFER SERGEFERRARI GROUP SA
POST OSTERREICHISCHE POST AG
FLU FLUGHAFEN WIEN AG
VLTSA VOLTALIA
MAU ETABLISSEMENTS MAUREL & PROM SA
DUFN DUFRY AG
RUI RUBIS SCA
BP. BP P.L.C.
TFF TFF GROUP
MEDCL MEDINCELL SA
ANTIN ANTIN INFRASTRUCTURE PARTNERS
SHEL SHELL PLC
BANB BACHEM HOLDING AG
CAN CANAL+
TRIO TRIODOS BANK N.V.
AUMOV AUMOVIO
- Robert Jan Vos
- Usama Tariq
Zealand Pharma to participate in upcoming investor conferences in Marc...
Zealand Pharma to participate in upcoming investor conferences in March 2026 Press release – No. 5 / 2026 Zealand Pharma to participate in upcoming investor conferences in March 2026 Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the company will participate in the following investor conferences in March 2026. 2026 Jefferies Biotech on the Beach Summit, March 9-11 in Miami Adam Steensberg, President and Chief Executive Officer, will host investor meetings...
- BC-bc user
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Wim Lewi
- Jacob Mekhael
Zealand Pharma Petrelintide shows modest weight loss but excellent tol...
Zealand reported mixed results from the phase 2 (ZUPREME-1) trial of petrelintide in overweight/obesity, showing a modest 10.7% weight loss at 42 weeks, while demonstrating excellent tolerability. We think this outcome makes first line positioning difficult, and view petrelintide as better suited for weight loss maintenance (subject to positive data in that setting). We adjust our peak sales estimate to $ 7b (from $ 22b), which brings down our TP to DKK 500 (from DKK 960). Given the lower upside...
Fagron publishes its Annual Report 2025
Fagron publishes its Annual Report 2025 Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET Fagron publishes its Annual Report 2025 Fagron, the leading global player in pharmaceutical compounding, today publishes its Annual Report 2025, further to its earlier announcement of Fagron's annual financial results for the financial year 2025 on February 12, 2026. The Annual Report is available on Fagron's in both Dutch (official version, including the ESEF-tagged version) and English. It comprises the annual financial report relating to the consolidated f...
Fagron publiceert haar Jaarverslag 2025
Fagron publiceert haar Jaarverslag 2025 Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 6 maart 2026 – 7:00 CET Fagron publiceert haar Jaarverslag 2025 Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, publiceert vandaag haar Jaarverslag 2025, volgend op de eerdere bekendmaking van Fagron's jaarlijkse financiële resultaten over het boekjaar 2025 op 12 februari 2026. Het Jaarverslag is beschikbaar op de van Fagron in zowel het Nederlands (officiële versie, inclusief ESEF-getagde versie) als in het Engels. Het Jaarverslag omvat het financieel...
Zealand Pharma announces positive Phase 2 results for petrelintide, an...
Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity Company announcement – No. 3 / 2026 Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity Petrelintide achieved up to 10.7% mean body weight reduction at week 42 (versus 1.7% with placebo) and demonstrated placebo-like tolerabilityAt the maximally effective dose, the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.